NASDAQ
JAGX
Last Price
US $6.02
KEY FIGURES
MKT CAP
$2.6M
EPS
TTM$-679.41
EPS Growth (1Y)
-82.42%
PEG
TTMN/M
P/E
TTMN/M
P/S
TTM0.01x
YIELD
—
Valuation
Financial
Performance
Cash flow to debt coverage
Jaguar Health, Inc. cash flow to debt ratio of 13.30% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Jaguar Health, Inc.'s free cash flow has increased 119.49% from $-29.61M last year to $5.77M, signaling increasing performance
Debt-to-equity ratio
Jaguar Health, Inc.'s debt to equity ratio is 2.52, which means that the company's assets are unhealthy financed, signaling financial risk.
Debt-to-equity trend
Jaguar Health, Inc.'s debt has decreased relative to shareholder equity from 5.01 last year to 2.52 today, signaling strengthened financials
Net debt to EBITDA
Jaguar Health, Inc. has negative EBITDA, making leverage ratio unreliable
Interest coverage
Jaguar Health, Inc.'s interest coverage ratio is -28.98, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
Jaguar Health, Inc.'s profit margin was -329.30% last year and is -131.76% this year, signaling increasing performance
Current ratio
Jaguar Health, Inc.'s short-term liabilities of $40.65M exceed its short-term assets of $20.34M, signaling financial risk
Return on assets
Jaguar Health, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Jaguar Health, Inc.'s return on equity of 762.51%, is higher than 15.00%, indicating good performance
Earnings quality
Jaguar Health, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Jaguar Health, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Jaguar Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
Jaguar Health, Inc. has a free cash flow yield of 172.70%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
Jaguar Health, Inc.'s yearly earnings has decreased 38.82% since last year from $-38.49M to $-53.43M, signaling decreasing performance
Revenue growth
Jaguar Health, Inc.'s yearly revenue has decreased 1.52% since last year from $11.69M to $11.51M, signaling decreasing performance
Return on invested capital
ROIC -109.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Jaguar Health, Inc.'s 3-year revenue CAGR of -1.26% is negative, indicating declining revenue over the past 3 years
Revenue consistency
Jaguar Health, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance
Return on equity consistency
Jaguar Health, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Base Cash Flow Valuation (DCF)
Jaguar Health, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Jaguar Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
Jaguar Health, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model
EV/EBITDA (FY)
Jaguar Health, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Jaguar Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Jaguar Health, Inc. has a price-to-book ratio of 0.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
Jaguar Health, Inc. has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
762.51%
Return on equity
ROIC: -109.75%
Valuation History
-
Price to Earnings
EV/EBITDA: -0.32X
Cash flow
Profit margin
GROWTH (5Y CAGR)
Revenue
4.17%
EBITDA
-11.09%
Cash flow
-
Base Cash Flow Valuation (DCF)
Fair Value
Market $6.02
—
Default assumptions
Base EBITDA Valuation
Fair Value
Market $6.02
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.